Similarly, recently published findings from the TRAIN-3 study echoed this observation.36 In this single-arm phase 2 study, while breast MRI was effective in identifying early complete responders among patients with HR-negative tumours, it failed to do so for patients with HR-positive, HER2-positive breast cancer. The gene discussed is ERBB2; the disease is neoplasm.